Patents by Inventor Jan H. Beumer

Jan H. Beumer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MELANOMA CHEMOPREVENTION
    Publication number: 20160287548
    Abstract: Disclosed herein are methods and uses for preventing melanoma, reducing progression of atypical nevi, and inducing cell cycle arrest and/or apoptosis in a melanoma cell through oral and enteral administration of sulforaphane to subjects indicated to be at risk due to factor(s) such as medical history of atypical nevi, melanoma, or UV exposure. Sulforaphane can be administered orally as a safe and well-tolerated natural agent as a chemopreventive strategy in individuals with atypical melanocytic nevi.
    Type: Application
    Filed: June 16, 2016
    Publication date: October 6, 2016
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Jan H. Beumer, John M. Kirkwood, Shivendra V. Singh, Charles K. Brown
  • Melanoma chemoprevention
    Patent number: 9393225
    Abstract: Disclosed herein are methods and uses for preventing melanoma, reducing progression of atypical nevi, and inducing cell cycle arrest and/or apoptosis in a melanoma cell through oral and enteral administration of sulforaphane to subjects indicated to be at risk due to factor(s) such as medical history of atypical nevi, melanoma, or UV exposure. Sulforaphane can be administered orally as a safe and well-tolerated natural agent as a chemopreventive strategy in individuals with atypical melanocytic nevi.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: July 19, 2016
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Jan H. Beumer, John M. Kirkwood, Shivendra V. Singh, Charles K. Brown
  • MELANOMA CHEMOPREVENTION
    Publication number: 20150141507
    Abstract: Disclosed herein are methods and uses for preventing melanoma, reducing progression of atypical nevi, and inducing cell cycle arrest and/or apoptosis in a melanoma cell through oral and enteral administration of sulforaphane to subjects indicated to be at risk due to factor(s) such as medical history of atypical nevi, melanoma, or UV exposure. Sulforaphane can be administered orally as a safe and well-tolerated natural agent as a chemopreventive strategy in individuals with atypical melanocytic nevi.
    Type: Application
    Filed: May 3, 2013
    Publication date: May 21, 2015
    Inventors: Jan H. Beumer, John M. Kirkwood, Shivendra V. Singh, Charles K. Brown